Search clinical trials for: 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose

Total 164 results

Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Imperial College London

Not yet recruiting

Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial (NOVEL)

Neoplasia
Johns Hopkins Bloomberg School of Public Health
Merck Sharp & Dohme LLC; Universidad Peruana Cayetano Heredia; NGO Via Libre

Completed

Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers (Girasol)

Human Papillomavirus Infection

Peru
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Papillomavirus Infections | Coronavirus Disease (COVID-19)

United States
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Recruiting

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS | HPV Infections | CIN 3

China
Merck Sharp & Dohme LLC

Active, not recruiting

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Genital Warts

China
University of Pittsburgh
Merck Sharp & Dohme LLC

Completed

Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting

Quadrivalent HPV Vaccine | Human Papillomavirus Vaccine

United States
Miquel Angel Pavon Ribas
Catalan Institute of Health; Hospital del Mar

Recruiting

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Human Papillomavirus (HPV) Infections | High-risk HPV | HPV-16/ 18

Spain
Sun Yat-sen University

Recruiting

The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age

Premature Ovarian Failure | Menstrual Disorder

China
Talia Sainz Costa

Recruiting

Immunogenicity of 9-valent HPV Vaccine

Human Papilloma Virus Infection

Spain
Augusta University

Unknown

9-valent HPV Vaccine in Postpartum Women

Human Papilloma Virus
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Healthy Volunteers | Meningococcal Immunisation

Spain, Hungary, Italy, Singapore
Simon Dobson
Ministry of Health, British Columbia

Completed

A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine (BCGov-01)

Cervical Cancer | Genital Warts

Canada
Instituto Nacional de Salud Publica, Mexico
National Council of Science and Technology, Mexico; Universidad Nacional Autonoma...

Completed

Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study (CONDESA)

Cancer of Cervix

Mexico
University of Alberta

Completed

Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients

Transplant

Canada
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Cervical Cancer | Genital Warts
American Scitech International
Johnson & Johnson

Unknown

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

Burns | Electric Burns

United States
University of Washington
Merck Sharp & Dohme LLC

Completed

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

HPV Infection | HPV Vaccination

Kenya
Washington University School of Medicine

Completed

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

HIV Infections | HIV Positive | Anal Condylomata | Anal Warts

United States
McGill University

Active, not recruiting

Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study (TRAP-HPV)

Human Papillomavirus Infection

Canada
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | AIS | Invasive Carcinoma | Cervical Cancers | CIN 3 | Vin III | Mild Dysplasia of Vulva | Moderate Dysplasia of Vulva

China
Public Health England

Completed

Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants

Streptococcus Pneumoniae
Universidad Nacional Autonoma de Mexico
Merck Sharp & Dohme LLC; Secretaria de Salud, Mexico

Unknown

Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City

Human Papilloma Virus

Mexico
Shanghai Bovax Biotechnology Co., Ltd.

Not yet recruiting

A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years

HPV Infection | HPV-Related Carcinoma | Genital Wart | HPV-Related Intraepithelial Neoplasia

China
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Papillomavirus Infections

United States, Belgium, Brazil, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Spain, Taiwan, Thailand
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Infections, Papillomavirus | Papillomavirus Vaccines

Thailand, Estonia, India, Brazil
Sinocelltech Ltd.
Sichuan Center for Disease Control and Prevention; Guangxi Center for Disease... and other collaborators

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

HPV-Related Carcinoma | HPV InfectioN

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Infection | Precancerous Condition

United States
University of Milan

Unknown

Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults

HIV | HPV

Italy
Merck Sharp & Dohme LLC

Completed

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Papillomavirus Infections
Merck Sharp & Dohme LLC

Active, not recruiting

Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) (FUTURE II)

Cervical Cancer | Genital Warts
Merck Sharp & Dohme LLC

Completed

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Papillomavirus Infections
Merck Sharp & Dohme LLC

Completed

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

HPV Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

China
St George's, University of London
European Union

Completed

Measuring Responses to Sublingual Antigens

Sexually Transmitted Diseases, Viral

United Kingdom
Zagazig University

Completed

Gardasil Versus Cervarix in the Treatment of Warts

Verruca Viral

Egypt
Xiamen Ophthalmology Center Affiliated to Xiamen...
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Active, not recruiting

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

Cervical Cancer | Condylomata Acuminata

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Beijing Health Guard Biotechnology, Inc

Active, not recruiting

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Human Papillomavirus Infection

China
Merck Sharp & Dohme LLC

Completed

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

HPV Infections
Merck Sharp & Dohme LLC

Completed

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Condylomata Acuminata
Merck Sharp & Dohme LLC

Completed

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

HPV Infections
Merck Sharp & Dohme LLC

Completed

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Cervical Cancer | Genital Warts
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
PATH

Completed

Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults

Shigellosis

United States
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)

Cervical Cancer | HPV | Premalignancy Anogenital Warts
Shanghai Zerun Biotechnology Co.,Ltd
Yuxi Zerun Biotechnology Co., Ltd.

Completed

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

HPV Infection

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Recruiting

Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)

Norwalk Gastroenteritis | Norovirus Infections

China
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Center for Disease Control and Prevention,...

Not yet recruiting

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Cervical Cancer | Cervical Intraepithelial Neoplasia | Persistent Infection

China

Search clinical trials for: 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations